Scrip
>>Neurological

Interview: C4XD Chief Sees Indivior Pact As First Of Many

29 Mar 2018

The deal for an oral orexin-1 receptor antagonist which aims to treat addiction by targeting the craving process validates C4XD's strategy of out-licensing preclinical programs. CEO Clive Dix told Scrip more agreements will follow as the firm "is not a one-trick pony."

Steps — Solid first step: C4XD signs its first major deal • Source: Shutterstock

Shares in C4X Discovery Holdings PLC have rocketed after the company licensed a potential best-in-class addiction candidate to fellow UK firm Indivior PLC in a deal that could be worth up to $294m.

The pact, for which C4XD is getting $10m up front and a further $284m of potential development, regulatory and commercialization...